Missed Opportunities for Hepatitis A Vaccination Among MSM Initiating PrEP

The incidence of Hepatitis A virus (HAV) among the general population in the United States has decreased by over 95% since the introduction of HAV vaccination in 1995. However, 10% of all new HAV infections occur among men who have sex with men (MSM). However routine HAV is not part of standard of c...

Full description

Saved in:
Bibliographic Details
Published in:Journal of community health 2020-06, Vol.45 (3), p.506-509
Main Authors: Cohall, Alwyn, Zucker, Jason, Krieger, Rachel, Scott, Charlotte, Guido, Caryn, Hakala, Shaina, Carnevale, Caroline
Format: Article
Language:English
Subjects:
Adult
Cohort Analysis
Cohort Studies
Community and Environmental Psychology
Ethics
Health Promotion and Disease Prevention
Hepatitis
Hepatitis A
HIV
HIV Infections
Homosexuality, Male
Human immunodeficiency virus
Humans
Immunity
Immunoglobulin G
Incidence
Male
Medicine
Medicine & Public Health
Original Paper
Patients
Public health
Retrospective Studies
Risk Factors
Risk groups
Seroepidemiologic Studies
Serology
Sexual and Gender Minorities
Sexually transmitted diseases
STD
United States
Vaccination
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of Hepatitis A virus (HAV) among the general population in the United States has decreased by over 95% since the introduction of HAV vaccination in 1995. However, 10% of all new HAV infections occur among men who have sex with men (MSM). However routine HAV is not part of standard of care for provision of PrEP services. Retrospective cohort analysis of MSM assessed for HIV prevention services between 1/1/2016 and 6/30/2017 to evaluate the rates of screening for anti-HAV seroprevalence and subsequent vaccination. HAV IgG was drawn on 96% (96/100) of the patients with 58% (56/96) of patients demonstrating serologic immunity. Of the 40 patients without evidence of immunity, 77% (29/40) returned for a subsequent visit, 48% (14/29) were provided HAV vaccination, and 29% (4/14) received at least two doses. Only 35% (14/40) of patients without documented immunity received HAV vaccination. Visits for PrEP initiation and monitoring in MSM patients are potential opportunities for ensuring HAV vaccination among this high-risk patient population. Public health agencies could optimize HAV vaccination of the high risk MSM by incorporating HAV screening into national PrEP guidelines.
ISSN:0094-5145
1573-3610
DOI:10.1007/s10900-019-00768-w